Outcome of 98 patients with epithelioid sarcoma treated in curative intent: A retrospective study from the French Sarcoma Group (GSF-GETO)

Pedrono, Maud; Mir, Olivier; Chaltiel, Léonor; Brahmi, M.; Italiano, Antoîne; Decanter, Gauthier; Rouquette, P. Boudou; Ropars, M.; Bompas, Emmanuelle; Firmin, Nelly; Isambert, Nicolás; Valentin, Thibaud; Duffaud, Florence; Gantzer, Justine; Thyss, Antoine; Guillemet, Cécile; Blay, Jean‐Yves; Cesne, Axel Le; Chevreau, Christine; Perrin, Christophe

doi:10.1093/annonc/mdz283.022

Search citation statements

Order By: Relevance

Paper Sections

Select...

Ezh2 Inhibitors1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2021

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For localized disease, surgical resection including amputations can be curative with a disease-free survival and overall survival rate of 54.5 months and 71%, respectively. However, local recurrence and distant metastases remain high [27]. In the advanced setting, outcomes are poor with median progression-free survival ranging from 3 to 6 months [28,29].…”

Section: Ezh2 Inhibitorsmentioning

confidence: 99%

Prospects for Epigenetic Targeted Therapies of Bone and Soft-Tissue Sarcomas

Wang

Elkrief

Guo

et al. 2021

Sarcoma

View full text Add to dashboard Cite

Targeted therapies have revolutionized cancer treatment. It is well established that alterations of chromatin configuration and modifications affect tumorigenesis of some, possibly most, bone and soft-tissue sarcomas. As epigenetic regulators play a major role in the development of bone and soft-tissue sarcomas, epigenetic drugs provide a novel potential avenue for rational targeted therapies for these aggressive cancers. The present review summarizes the application of epigenetic drugs for clinical utilization in bone and soft-tissue sarcomas and provides an overview of clinical trials currently evaluating epigenetic therapies in this space.

show abstract

Section: Ezh2 Inhibitorsmentioning

confidence: 99%